Ventirx Pharmaceuticals, Inc.

Array Biopharma Inc.

Sudo Biosciences Limited

University of Pennsylvania

Gregory Dietsch

Robert Hershberg

Laurence Edward Burgess

James Jeffry Howbert

Anjali Pandey

Athisayamani Jeyaraj Duraiswamy

Seetharaman Manojveer

Sukesh Kalva

Mahesh Thakkar

Joseph P Lyssikatos

Brad Newhouse

George A Doherty

J Jeffry Howbert

Robert D Groneberg

Hong-Woon Yang

Bhaskar Chaudhuri

Hong Woon Yang

George Coukos

C Todd Eary

Zachary Jones

Andrea Facciabene

Kristi Manjarrez

Tressa D Randall

Described herein are compounds of Formula (I) that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.

Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors

Described herein are compounds of Formula (XIV) that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.

Substituted pyridines and pyridazines as TYK2 inhibitors

Described herein are compounds of Formula (XIII) that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.

Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors

Described herein are compounds of Formula (XVII) that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of Using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity. 

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.

Substituted benzoazepines as toll-like receptor modulators

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

Toll-like receptor agonist formulations and their use

Growing community of inventors

Snohomish, WA, United States of America

Gregory Dietsch